A drug discovered by Cancer Therapeutics CRC scientists has entered Phase 2 clinical trials.
Amplia Therapeutics Limited recently announced the recruitment of the first patient to the ACCENT trial, a Phase 1b/Phase 2a clinical trial of focal adhesion kinase inhibitor AMP945. The use of AMP945 in the trial is intended to enhance the efficacy of chemotherapy for people with advanced pancreatic cancer undergoing first-line treatment.
AMP945 was invented by scientists from the Cancer Therapeutics Cooperative Research Centre (2007-2020) and the program was licensed to Amplia Therapeutics to take into clinical development.
To read more about the development of AMP945 and the clinical trial, click on the links below: